TCR2 Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

TCR2 Therapeutics

23/03/2023 11:07

* TCR2 Therapeutics Inc  TCRR.OQ  reported a quarterly
adjusted
loss of $1.56​​ per share for the quarter ended in December. The
mean expectation of ten analysts for the quarter was for a loss
of 79 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * TCR2 Therapeutics Inc's reported EPS for the quarter was a
loss
of $1.56​.
    * The mean earnings estimate of analysts had fallen by
about 5.6%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * TCR2 Therapeutics Inc shares had risen by 47.2% this
quarter.
    * The company reported a quarterly loss of $60.51 million.
    * Wall Street's median 12-month price target for TCR2
Therapeutics
Inc is $3.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 6
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 23 at 11:07 a.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.79          -1.56          Missed
 Sep. 30 2022      -0.83          -0.79          Beat
 Jun. 30 2022      -0.79          -0.82          Missed
 Mar. 31 2022      -0.74          -0.76          Missed